Biotechnology CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based S-Trimer COVID-19 vaccine candidate by China’s Clover Biopharmaceuticals, through a global pivotal Phase II/III efficacy clinical trial and to licensure in China and globally, if the vaccine is proven to be safe and effective. 3 November 2020